Ignite Creation Date:
2024-05-06 @ 1:51 PM
Last Modification Date:
2024-10-26 @ 1:21 PM
Study NCT ID:
NCT04144517
Status:
COMPLETED
Last Update Posted:
2024-01-25
First Post:
2019-10-24
Brief Title:
A Study of ALKS 4230 Nemvaleukin Alfa With Pembrolizumab in Head and Neck Cancer
Sponsor:
Mural Oncology Inc
Organization:
Mural Oncology Inc
Study Overview
Official Title:
A Phase 2 Study of ALKS 4230 in Combination With Anti-PD-1 Pembrolizumab in Patients With Advanced or Recurrent Head and Neck Squamous Cell Cancer Currently on Treatment With Anti-PD-L1 Without Having Achieved a Complete Remission
Status:
COMPLETED
Status Verified Date:
2024-09
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The primary objective of this study was to estimate the response rate to ALKS 4230 in combination with pembrolizumab in patients with HNSCC who had previously received anti-PD-L1 therapy but who had not achieved a CR
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
True
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None